The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
 
Nima Sharifi
Consulting or Advisory Role - Roivant
Research Funding - Astellas Pharma (Inst); Bristol Myers Squibb Foundation (Inst)
Patents, Royalties, Other Intellectual Property - A patent application has been filed by Cleveland Clinic for a method of steroid-dependent disease treatment based on HSD3B1. Nima Sharifi is a co-inventor on this patent application
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Mona Patel
Consulting or Advisory Role - Astellas Pharma
 
Jason W.D. Hearn
Consulting or Advisory Role - The Dedham Group
 
Michele Wozniak
Employment - Astellas Pharma
Stock and Other Ownership Interests - ADMA Biologics; CASI Pharmaceuticals; Merck; Seelos Therapeutics
 
Fabian Zohren
Employment - Pfizer
Stock and Other Ownership Interests - AlloVir (I); Pfizer
Patents, Royalties, Other Intellectual Property - AlloVir Inc (I)
 
Jennifer Sugg
Employment - Astellas Pharma
Stock and Other Ownership Interests - AstraZeneca
 
Gabriel P. Haas
Employment - Astellas Pharma
 
Arnulf Stenzl
Consulting or Advisory Role - Alere; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; Roche; Steba Biotech; Synergo
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bayer (Inst); Cepheid (Inst); GenomeDx (Inst); immatics (Inst); Janssen; Johnson & Johnson (Inst); Karl Storz (Inst); Medivation; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - 2018/6579 Gene-expression signature for subtype and prognostic prediction of renal cell carcinoma; AT00/0001:C-Trap, implantable device to treat urinary incontinence; Patent A290/99 Implantable incontinence device
Expert Testimony - GBA Pharma
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; CureVac; Ferring; Ipsen; Janssen; Sanofi/Aventis
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Exelixis; FORMA Therapeutics; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc